Ending Aging Forum 2022

Ending Aging Forum 2022

Research & Education

September 2nd - 3rd, 9am – 2:30pm PST

EXVO Virtual Reality Platform

Thank you for a wonderful and thought provoking time with the team at SENS Research Foundation. This virtual event allowed us to share first-hand, the latest advances that our in-house researchers are making toward new rejuvenation biotechnologies, along with some of our young scientists-in-training and outside researchers whose research we fund. In addition to the formal presentations, we enjoyed the opportunity to facilitate one-on-one discussions with the scientists and other members of our team, as well as with citizens, donors, and activists who dream of and work for a future free of degenerative aging.

Breaking down the barriers to attendance, we hosted the virtually through EXVO, a strong platform for this VR experience. The virtual event’s presentations were made in our Conference Hall, along with project-specific Research Booths and booths for scientific posters presented by our students that broke down different research projects.

In the Expo Room, attendees were also able to meet and talk one-on-one or in small groups with the team and other supporters, or watch videos in which our team members and scientists-in-training introduce themselves and what drew them to this Mission.

Stay tuned for upcoming YouTube videos of the presentations to learn and celebrate how far we’ve come, and to catch a glimpse of the future we’re building!

Intramural Speakers

Dr. Amit Sharma

Dr. Amit Sharma

Group Lead, Senescence Immunology Research

Amit received his PhD from the University of Pune for demonstrating microRNA regulation of cytokines and regulation of allergic inflammation. During his postdoctoral research at Stanford University, he demonstrated age-related resistance in the reprogramming of fibroblasts with classical Yamanaka factors. To peruse his interest in aging, he did a second postdoc at the Buck Institute in investigating molecular regulatory pathways involved in genotoxic stress and cellular senescence in invertebrate and mammalian models. He joined SENS Research Foundation as Group Lead in 2019 and his laboratory focuses on developing strategies to harness the immune system in mitigating the deleterious effects of senescent cells.

Dr. Tesfahun Admasu

Research Fellow​

Dr. Admasu earned his PhD in Biochemistry from national university of Singapore. In his PhD work he investigated interactions between lifespan extending drugs with the aim of engineering synergistic benefits in C. elegans. Dr. Admasu is currently a research fellow at SENS Research Foundation. His research focus on isolation and characterization of secondary senescent cells using surface markers and identification of novel approaches to ablate multiple types of senescent cells. He recently identified a novel senolytic approach to kill multiple types of senescent cells.

Dr. Amutha Boominathan

Group Lead, MitoSENS

Dr. Amutha Boominathan is the Group Lead for the MitoSENS program at SENS Research Foundation. She joined the organization in 2013 as a Senior Research Scientist and became the Group Lead for the program in 2016. She has a PhD in Biochemistry and has over 22 years of experience in mitochondria biology.

Dr. Abdelhadi Rebbaa

Group Lead, RepleniSENS

Dr. Rebbaa received his PhD from Claude Bernard University, Lyon, France, and held research and faculty positions at Northwestern University, the University of Pittsburgh and Columbia University.  Over the course of his career, his research encompassed target and drug discovery and development in the fields of cancer, stem cells and aging. Recently, he oversaw the discovery and preclinical testing of small molecule senolytics and biomarkers of aging.

Dr. Rebbaa served as a Principal Investigator on multiple grants, published over 40 manuscripts and reviewed manuscripts in respected scientific journals. He is currently applying the acquired experience to study the effect of a combination therapy using senolytics and stem cell transplantation on reducing senescent cell burden and the functional decline caused by aging.

Extramural Speakers

Dr. Tilman Grune

Scientific Director, German Institute of Human Nutrition Potsdam-Rehbruecke (DiFE)

Dr. Grune trained as a biochemist in Moscow. Later he obtained his PhD and D.Sci. at the Charité Berlin. After Post-Doc positions in Berlin and Albany; NY he is heading its own laboratory in Berlin and Düsseldorf. After professorships in Stuttgart and Jena, he is now the Scientific Director of the German Institute of Human Nutrition and the head of the Department of Toxicology. Since 2020 he holds also a position of a professor of Physiological Chemistry and Cellular Biochemistry at the University of Vienna, Austria. His scientific interest is focused on the aging of post-mitotic cells, nutritional effects on aged cells and biomarkers of nutrition, aging and redox status. He is founding Co-Editor- in-Chief of Redox Biology and has published some 450 publications.

Dr. Jean Hebert

Professor, Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine

Jean trained as a molecular geneticist, obtaining his Ph.D. from the University of California, San Francisco, before specializing in the study of how neural stem cells form the brain at Stanford University. He is now a Professor at the Albert Einstein College of Medicine in New York.

Dr. Jonathan Clark

Head of Biological Chemistry Facility, Babraham Institute, Cambridge

Jonathan studied Biological Chemistry at the University of Leicester and then obtained a PhD in new synthetic methods towards the synthesis of Taxol. He then spent 11 years working in the biotechnology sector around Cambridge, UK before joining the Babraham Institute where he now runs the Biological Chemistry group. His group has been studying the ageing of collagen with the aim of understanding how chemical changes which occur in collagen with age impact function.

Dr. Andrei V. Gudkov

Garman Family Chair in Cell Stress Biology, Roswell Park Comprehensive Cancer Center

Dr. Gudkov obtained his Ph.D. and D.Sci. degrees in Moscow, USSR. Since 1990, works in the US: first, at University of Illinois at Chicago, then in Cleveland Clinic and, since 2007, at his current position of Sr.VP, Professor of Oncology and Chair of Department of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. His interests involve anti-cancer and anti-aging research, radiation biology, virology and mechanisms of inflammation. He published >250 papers, serves on editorial boards of Aging, Oncogene, Oncotarget (Co-Editor-in Chief), etc., and founded several biotech companies that develop anticancer and anti-aging drugs based on his inventions.

Students Presenting Posters

Oliver Frost

Ph.D. Student

Ashley Brauning

Masters Student

Marek Pinto

Summer Scholar

Keefer Li

Summer Scholar

Benjamin Ramsell

Summer Scholar

Mustafa Mahmood

Summer Scholar

Alec Eames

Summer Scholar

Sheryl Lin

Summer Scholar

Chinkuli Munkombwe

Summer Scholar

Nikita Sajeev

Summer Scholar

Grace Goetz

Summer Scholar

Rushmeen Tariq

Summer Scholar

Bronwyn Mogck

Summer Scholar

Anastasiia Rudenko

Summer Scholar

Schedule

September 2nd - 3rd, 9am – 2:30pm PST

(schedule subject to change prior to the event)

Posters prepared by graduates of our Education programs will be available to view throughout the event.

Friday Sept 2nd: Day 1

9am – 9:30am: Meet & Greet at Conference Hall / Booths Open

Student Booths Featured:
  • Marek Pinto
  • Keefer Li
  • Benjamin Ramsell
  • Mustafa Mahmood
  • Chinkuli Munkombwe
  • Nikita Sajeev

9:30am – 10:30am: ApoptoSENS

Dr. Amit Sharma – 1 hour (45 min talk plus 15 min Q+A)

10:30am – 11:30am: Dr. Tilman Grune

1 hour (45 min talk plus 15 min Q+A)

11:30am – Noon: 30-minute break

Student Booths featured:

  • Grace Goetz
  • Browyn Mogck
  • Rushmeen Tariq
  • Sheryl Lin
  • Oliver Frost
  • Ashley Brauning
  • Anastasiia Rudenko

Noon – 12:45pm: ApoptoSENS

Dr. Tesfahun Admasu: 45 min (30min talk plus 15 min Q+A)

12:45pm – 1:45pm: Dr. Jean Hebert

1 hour (45 min talk plus 15 min Q+A)

1:45pm – 2:30pm: Booths Open

End of Event Day 1

Sat Sept 3rd: Day 2

9am – 9:30am: Meet & Greet at Conference Hall / Booths Open

Student Booths Featured:
  • Grace Goetz
  • Browyn Mogck
  • Rushmeen Tariq
  • Sheryl Lin
  • Oliver Frost
  • Ashley Brauning
  • Anastasiia Rudenko

9:30am – 10:30am: MitoSENS

Dr. Amutha Boominathan – 1 hour (45 min talk plus 15 min Q+A)

10:30am – 11:15am: RepleniSENS

Dr. Abdelhadi Rebbaa 45 min (30min talk plus 15 min Q+A)

11:15am – 11:45am: 30-minute break

Student Booths featured:

  • Marek Pinto
  • Keefer Li
  • Benjamin Ramsell
  • Mustafa Mahmood
  • Alec Eames
  • Chinkuli Munkombwe
  • Nikita Sajeev

11:45am – 12:45pm: Dr. Jonathan Clark

1 hour (45 min talk plus 15 min Q+A)

12:45pm – 1:45pm: Dr. Andrei Gudkov

1 hour (45 min talk plus 15 min Q+A)

1:45pm – 2:30pm: Networking

End of Event Day 2

Intramural Speakers' Summaries

Dr. Amit Sharma

Eliminating senescence: more ways to kill death resistant cells from novel senolytics to immune based therapeutics.

Many aging pathologies are causally linked to the accumulation of senescent cell burden with increasing age. The senescent cells are characterized by molecular and structural changes culminating in an irreversible cell-cycle arrest and secretion of complex pro-inflammatory senescence-associated secretory phenotype (SASP), which contributes to chronic inflammation and damage to surrounding cells and tissues. Thus, the removal of senescent cells via drugs that selectively kill senescent cells (“senolytic” drugs) to prevent or delay tissue dysfunction has shown great promise in improving age-related pathologies and extending health span.

The research goals of my laboratory are to (A) investigate the cellular mechanisms that cause age-dependent increase in cellular senescence burden and (B) investigate interventions that reduce or eliminate senescent cells.

Several lines of evidence show that Natural Killer (NK) cells play a vital role in the immune surveillance of these cells. Despite these recent studies, therapeutic strategies to exploit NK cells to reduce the senescence burden have not yet emerged. We are investigating mechanisms involving NK cell-mediated targeting of senescent cells to improve NK cell-mediated senotherapeutics for the treatment of aging and inflammatory disorders.

Dr. Tesfahun Admasu

Dissecting primary and secondary senescence to enable novel senotherapeutic strategies.

Senescent cells can spread the senescent phenotype to other cells by secreting factors called the Senescence Associated Secretory Phenotype (SASP). The resulting secondary senescent cells make a significant contribution to the burden of senescent cells accumulation with age. Efforts made to characterize secondary senescence have mostly been unreliable due to their analysis based on mixed populations of senescent and non-senescent cells. Here, we used dipeptidyl peptidase-4 (DPP4) as a surface maker to isolate senescent cells from mixed populations. Using this novel technique, we enriched the percentage of secondary senescent cells from 40% to 85%, which is comparable to senescence induction levels in primary senescent cell cultures. We then used this enriched culture to dissect the molecular and phenotypic differences and similarities between DPP4+ isolated primary and secondary senescent cells. Notably, we found that secondary senescent cells have distinct prosurvival mechanisms and are substantially less susceptible to current senolytics than are primary senescent cells. Finally, we identified a novel and broad- spectrum senolytic approach to ablate both primary and secondary senescent cells.

Dr. Amutha Boominathan

Allotopic expression of mtDNA genes.

Mitochondrial dysfunction has been implicated in several age-related diseases and aging in general. Accumulation of mutations in the mtDNA with age adversely affects the organelle function and the MitoSENS group at SENS Research Foundation endeavors to identify translational avenues in maintaining the fitness of mitochondria over time using a gene therapy approach. Utilizing codon optimization to synchronize the nuclear and mitochondrial DNA genes, the team recently reported robust transient expression for all the 13 protein coding genes in the mitochondrial DNA. In patient derived cybrid cells and animal models with specific mutations the team was further able to demonstrate that allotopic gene expression for one of the two Complex V mitochondrial DNA genes, namely ATP8, restored several functions including protein expression, complex integration, and recovery of OxPHOS function. Efforts to achieve stable expression with functional relevance for the rest of the 12 genes are ongoing.

Dr. Abdelhadi Rebbaa

Combination of senolytics and stem cell transplantation as a potential anti-aging therapy

The accumulation of damaged/senescent cells in the body with time is a hallmark of aging. Since these cells produce pro-inflammatory and pro-fibrotic molecules, they are believed to contribute to the onset and/or the severity of the chronic diseases that accompany old age. Based on this, the development of strategies to eliminate senescent cells for instance by using senolytics has opened new possibilities for anti-aging therapeutic development. Prior to the discovery of senolytic agents, evidence was provided that local or systemic transplantation of mesenchymal stem cells improve the outcome of various aging associated diseases. Although the underlying mechanism of their action is still not well defined, it is believed to be mediated by paracrine and immunomodulatory effects.

Here we set out to test the hypothesis that the combination of senolytics with mesenchymal stem cell transplantation will have a synergistic effect in extending mouse health span. In vitro and in vivo studies are underway to identify adequate biomarkers and imaging techniques to monitor response to the anti-aging interventions to be tested. We are also conducting cell-based analyses to select a senolytic candidate and to assess the quality and suitability of the MSC cells to be used in in vivo. Finding from this study will allow for evaluating the efficacy of candidate senolytics in reducing senescent cell burden in mice and whether their combination with stem cells will enhance health span of the treated animals.

Extramural Speakers' Summaries

Dr. Tilman Grune

LIpofuscin – an active player in senescent cells and how to get rid of it

Lipofuscin is an aggregate of cross-linked, non-functional proteins and other cellular components accumulating mainly in post-mitotic cells. Many of other studies revealed that it is impairing cellular function and, therefore, contributes to the age-associated functional organ decline. Besides studying the effects of lipofuscin in post-mitotic cells we are in the process of developing strategies to reduce the lipofuscin burden.

Dr. Jean Hebert

Brain cell and tissue replacement as a cornerstone to beating aging.

The neocortex is the part of our brain that performs our highest cognitive functions. In recent years, the mechanisms underlying how stem cells in the embryo generate the neocortex have become better understood. Armed with this knowledge, the Hébert Lab is developing approaches to replace and repair adult neocortical tissue after age-related degeneration.

Dr. Jonathan Clark

A different perspective on the changes in tendon collagen crosslinking with age and the impact on function.

In his presentation Jonathan will discuss and interpret results from his group on the changes in tendon collagen crosslinking with age and the impact on function. In this work it is shown that statements often made about crosslinking and ageing are over simplifications and that the situation is actually more subtle and dynamic than previously recognised. This work suggests that if you are to rejuvenate tendon collagen, that you probably have to tackle the changes at multiple levels and not just remove irreversible crosslinks. Two publications from his group relevant to this presentation can be found at: https://pubmed.ncbi.nlm.nih.gov/32381510/ and https://pubmed.ncbi.nlm.nih.gov/32546479/

Dr. Andrei V. Gudkov

Endogenous “retrobiome” as a putative aging driver.

Nearly half of the human genome is occupied by retrotransposons, highly repetitive interspersed virus-like genetic elements that replicate via reverse transcription. This “retrobiome” is epigenetically repressed in normal cells but is frequently desilenced in cancer cells. In addition to tumors, retrobiome expansion also occurs in aging somatic cells contributing to aging-associated DNA damage and inflammation. Our team isfocused on developing mouse models that would enable testing the role of derepression of retroelements in aging and testing antiaging therapies targeting retrobiome activity.

Student Bios

Oliver Frost

Ph.D. Student from Loughbrough University, hosted by Abdelhadi Rebbaa at SENS Research Foundation

Oliver is a PhD student from the University of Loughborough, a top ten university in the UK. Based in the RepleniSENS team with Dr. Rebbaa, his project focuses on the synergistic effects of senolytics followed by a stem cell transfer to improve health and lifespan in mice.

Ashley Brauning

Masters Student from Dominican University of California, hosted by Amit Sharma at SENS Research Foundation

Ashley received her B.S in Molecular and Cellular Biology from the University of Puget Sound and is currently working on her M.S at Dominican University. She joined SRF in September 2021 as a post-baccalaureate research fellow and graduate student researcher with the ApoptoSENS group using surfaceomics techniques to characterize the surface of senescent cells.

Marek Pinto

Summer Scholar from Boston University, hosted by Amutha Boominathan at SRF

Marek Pinto is a rising sophomore at Boston University studying Biomedical Engineering and Computer Science. Marek is fascinated by the mechanisms behind aging and has been excited to contribute to research through the SRF program this summer!

Keefer Li

Summer Scholar from University of Massachusetts, Amherst, hosted by Amutha Boominthan at SRF

Keefer Li is a junior Biochemistry and Molecular Biology major in the Commonwealth Honors College at the University of Massachusetts Amherst. Keefer has been super excited to spend his summer living and learning with fellow anti-aging enthusiasts in Mountain View, California.

Benjamin Ramsell

Summer Scholar from Oregon State University, hosted by Abdelhadi Rebbaa at SRF

The mechanisms of aging is a field of research that Benjamin Ramsell has been fascinated with since he was twelve. At SRF, he feels that he has the opportunity to study these mechanisms directly and contribute to the development of medical science.

Mustafa Mahmood

Summer Scholar from Siena College, hosted by Abdelhadi Rebbaa at SRF

Mustafa Mahmood is a rising senior majoring in Biology. Mustafa is most excited about getting some hands-on experience in aging research and increasing the breadth of his research experience with the SRF program!

Alec Eames

Summer Scholar from University of Michigan Ann Arbor, hosted by Cyclarity

Alec Eames is a biomedical engineering student at the University of Michigan. Alec is looking forward to contributing to the cutting-edge aging research SRF is conducting in aging biology!

Sheryl Lin

Summer Scholar from Johns Hopkins University, hosted by Aspen Neurosciences

Sheryl Lin is a rising junior studying Molecular and Cellular Biology at Johns Hopkins. Sheryl is thrilled to be contributing to the fight against Parkinson’s Disease and working with cutting-edge autologous neuron replacement therapies at Aspen Neuroscience.

Chinkuli Munkombwe

Summer Scholar from Georgia State University, hosted by Evan Snyder at Sanford Burnham

Chichi Munkombwe is a neuroscience major at Georgia State University. As part of the SRF Summer Scholars Program, Chichi looks forward to learning new methods of tackling the questions in her field and collaborating with other members of her cohort!

Nikita Sajeev

Summer Scholar from Temple University, hosted by Evan Snyder at Sanford Burnham

Nikita Sajeev is currently a senior neuroscience major at Temple University in Philadelphia, though her hometown is Portland, Oregon. Nikita is interested in science communication and clinical care, and hopes to eventually be a physician scientist.

Grace Goetz

Summer Scholar from University of Connecticut, hosted by Evan Snyder at Sanford Burnham

Grace Goetz, is a rising senior at the University of Connecticut. Grace is a biomedical engineering major with a concentration in biomaterials and tissue engineering, and researcher with the Tissue Engineering Sciences and Technology lab on campus.

Rushmeen Tariq

Summer Scholar from University of Utah, hosted by Christopher Wiley at Tufts University

Rushmeen Tariq is a biology major at the University of Utah. Rushmeen has been really excited to do research and explore Boston this summer!

Bronwyn Mogck

Summer Scholar from Villanova University, hosted by Christopher Wiley at Tufts University

Bronwyn Mogck and is a junior at Villanova University double majoring in Biology and Humanities. Bronwyn is interested in looking at the way that lab research leads to changes in everyday lives, and admires the way SRF values communication with the non-scientific community.

Anastasiia Rudenko

Summer Scholar from Pace University, hosted by Jennifer Garrison/Polina Lishko at The Buck Institute for Research on Aging/UC Berkley

Anastasiia Rudenko comes to us from Kyiv, Ukraine. She is currently majoring in Behavioral Neuroscience with a Minor in Computer Science at Pace University. Anastasiia is excited to aid in developing a new level of research opportunities in Neurobiology.

Media Partner:

Categories SRF

An SRF-sponsored new organization and Longevity Summer Camp

SRF is a proud sponsor of LessDeath and the Longevity Summer Camp! LessDeath is a new organization and event series dedicated to helping people join the Longevity Biotechnology industry through education, career and community strategizing, job opportunities, and more.

You don’t need a biology PhD to get involved! The industry needs many types of scientists, engineers, programmers, founders, technicians, operations experts and more. If you’re passionate about maximizing human health and lifespan, LessDeath’s mission is to help you find effective ways to contribute!

LessDeath’s Longevity Summer Camp will be hosted July 20th-24th in California. Our very own Vice President of Research, Dr. Alexandra Stolzing, will be one of the camp counselors. Visit the link below to learn more and to apply to the summer camp.

Follow them on Twitter: @LessDeath.org

Announcing the new Chairman of the SRF Board of Directors

SRF is pleased to announce that Bill Liao has been appointed Chairman of the Board of Directors.

He’s been serving as a Director and Board Secretary since the beginning of SRF. Bill Liao is a Chinese-Australian-Irish entrepreneur, investor, former diplomat, business mentor, author, passionate leader and speaker, with a distinguished record in business development and community activism. He is co-founder of the CoderDojo movement which teaches children worldwide how to code, and of Weforest, which has a stated goal of planting a hundred million trees around the equator. He has been a member of official delegations to the COP climate change summits. His career in tech and business encompasses two unicorn companies and launching the world’s first bio-tech accelerator. He has participated as an investor and volunteer for The Hunger Project in Uganda, New York, and Mexico. He is a general partner of SOSV, a venture capital fund of over $1B, and founder of the SOSV Momentum Pre-accelerator program. Bill’s current focus is Quantum Software.

Barbara Logan who is stepping down as Chair, has been serving as a Director since the founding days of the organization and we are profoundly grateful for her leadership, guidance and support during all these years, and recently through some of the most difficult times the organization had to face. She remains a Board member.

The members of our Board are dedicated and esteemed persons who bring extensive, diverse experience and commitment to guiding SRF.

We are excited to keep harnessing their knowledge and energy into furthering our mission.

Aging of the Immune System: Focus on Natural Killer Cells Phenotype and Functions

We are proud to announce the recent publication by the ApoptoSENS team led by Dr. Amit Sharma in the journal Cells describing the role and controversies involving the aging of Natural Killer (NK) cells and age-related NK cell dysfunction.

NK cell dysfunction is implicated in the increasing burden of infection, malignancy, inflammatory disorders, and senescent cells with age.

This review focuses on recent advances and open questions in understanding the interplay between systemic inflammation, senescence burden, and NK cell dysfunction in the context of aging and potential therapies for age-related diseases.

Authors: Ashley Brauning, Michael Rae, Gina Zhu, Elena Fulton, Dr. Tesfahun Dessale Admasu, Prof. Alexandra Stolzing, Dr. Amit Sharma contributed to this publication.

DOI: 10.3390/cells11061017

Categories SRF

A Message from the SRF Board of Directors

The offer of a Director position was refused by Dr. Aubrey de Grey, as stated in a public forum and taken as response in absence of other communication.

Invitation for Dr. De Grey and Richard Heart to join the Board of Directors

The SENS Research Foundation Board of Directors has a singular focus – to help the Foundation develop, promote, and ensure widespread access to therapies that cure and prevent the diseases and disabilities of aging. As the body responsible for ensuring the organization’s alignment with its mission, it is important our Board comprise leaders within the longevity field – visionaries dedicated to defeating the effects of aging permanently.

Many supporters have followed with interest our recent separation from our co-Founder Dr. Aubrey de Grey, and some have expressed concern regarding the possibility of our mission focus drifting off course. We remain firmly on-mission and continue to make real progress in our field, however, we acknowledge that we are the foundation we are today because of Dr. de Grey’s vision and leadership within the longevity movement. With this in mind, we have formally offered Dr. de Grey a Directorship within the Board of Directors.

His installment as a Director will be effective immediately upon the successful completion of the recommendations made by the accredited professional he has personally engaged, with a subsequent letter of recommendation to the Board of Directors supporting Dr. de Grey’s ability to fulfill the duties of Directorship. In this capacity, Dr. de Grey would lend his expertise to help steer the vision of the Foundation. Consistent with good governance and past practices, Dr. de Grey and the other members of the Board will approve the annual budget, review the annual audit, interview and hire executives, act as advocates for SRF, and largely ensure that the mission is being adhered to by the organization.

With an eye toward continued growth, we have also extended an invitation to Richard Heart to join the SRF Board. Richard is a passionate advocate within the longevity movement, a visionary in his own right, and the organizer of the largest fundraising campaign in SRF history. Both SRF and the longevity movement at large would benefit greatly from Richard joining our Board, and we are grateful for his sincere consideration.

We share these invitations with the public both in the interest of transparency and to be clear about the desired direction of our Board and, by extension, our continued growth in and service to the longevity field.

We will share more as we continue to plan for our future. Until then, thank you for your support of our important work.

The SENS Research Foundation Board of Directors

We are thrilled to announce the expansion of our Research Center

We are thrilled to announce the expansion of our Research Center to over 11,000 sq. feet with the addition of new lab and office space. This is more than doubling our current facility in Mountain View California that is home to SRF’s global operations. 

Thank you to all the donors who made this expansion possible. We are grateful beyond words for your ongoing support, as it has enabled us to rapidly expand not just our lab space, but our internal research programs, as well as the equipment and other resources needed to accelerate the defeat of age-related disease.

We will host a Grand Re-Opening early this summer to which everyone will be invited – watch your inbox and stay tuned for details.

Job Opportunity: Research Scientist – MitoSENS

Job Type: Full-time
Title: Research Scientist
Salary: Pay is salaried, commensurate with experience and local rates.

The Opportunity:

SRF is a non-profit organisation globally recognized for its dedication to transforming the way the world researches and treats aging (www.sens.org). We are located in Mountain View, California, in the heart of bay area biotech hub and several premier academic institutions.

Mitochondria are dynamic organelles vital to several functions within the cell. Decline in mitochondrial function is a distinctive feature in several age-related pathologies including sarcopenia, metabolic dysfunctions, and neurodegenerative disorders. It has been observed that, with age, mutations in the mitochondrial DNA accumulate at an order of magnitude higher compared to the nucleus. The Boominathan lab at SENS Research Foundation is developing gene therapies to functionally express the 13 protein coding genes in the mitochondrial genome from the nucleus (also called allotopic expression). We are also interested in modulating the mitochondrial DNA for sustained organelle fitness and function over time. Using disease cell lines and in vivo models, our lab integrates molecular biology, biochemistry, and computational tools in achieving these goals. For project details please see https://sens.org/research/intramural/allotopic-expression.

Key Responsibilities:

This research position is within a collaborative and dynamic group developing transitional therapies for mitochondrial dysfunctions.

  • Plan, design and execute all aspects of preclinical research
  • Analyze data, prepare reports, and present results regularly in internal and external settings
  • Mentor junior staff and maintain day to day functions in the laboratory

Technical Skills and Qualifications:

  • The ideal candidate should have a Ph.D. in biology/ biochemistry/ biomedical/ bioengineering or a related field
  • Proven experience in cell and molecular biology, gene therapy / DNA editing, working with rodent models, and assay development
  • Familiarity in designing large DNA constructs (BAC cloning, artificial chromosomes) is highly desired
    Experience with biomolecule delivery using vesicles, exosomes, nanoparticles, or similar technologies is highly desired
  • Exposure to mitochondria biology is a plus but not required
  • Excellent written and verbal communication skills
  • Excellent interpersonal and organizational skills with the ability to thrive in a goal-driven team environment
  • Excellent analytical and problem-solving skills
  • Ability to plan and document your work diligently
  • Positive spirit, a real drive for science
  • Capacity to adapt as priorities and requirements change

Compensation:

We offer an excellent benefits package including paid vacation and sick leave, fully covered health and dental insurance (inclusive of dependents), an FSA program, and a company-matched 401(k) plan, all of which is offered after a 90-day introductory period. SENS Research Foundation is an equal opportunity employer. We may sponsor a visa for international applicants.

The position is available now and will be filled as soon as qualified candidates are found. Salary is commensurate with job experience.

TO APPLY:

If you are interested in this opportunity, please send a current CV and a letter expressing your interest to [email protected].

Announcement from the SRF Board of Directors

March 25, 2022

Over the past two years, SRF’s volunteer Board members have devoted unprecedented selflessness – including countless hours and great emotional energy – to their duties as the foundation’s unpaid fiduciaries.

We want to extend our deepest gratitude to our colleagues who, as of March 23, have stepped down from the Board to focus more on their professional endeavors and personal lives.

Michael Boocher
Jonathan Cain
Mike Kope
Frank Schuler

As always, the remaining Directors, together with our remarkable SRF staff, will stay sharply focused on our original mission of curing the disease of aging.

The SENS Research Foundation Board of Directors

 

Announcement from the SRF Board of Directors

In August 2021, the SENS Research Foundation Board of Trustees separated from Dr. Aubrey de Grey, our Co-Founder and then-Chief Science Officer. This was a difficult decision, but, as we said at the time, a necessary one.

In doing so, we wholeheartedly acknowledged that we are an organization that is, and always will be, shaped by Dr. de Grey’s vision for transformation within the longevity field. In that spirit, in December 2021, we began a cautious, but important process of re-unifying with Dr. de Grey – a process aimed at helping both Dr. de Grey and the Board move forward from a difficult and contentious period and refocus our collective efforts on bolstering research that can permanently cure the effects of aging. Dr. de Grey would rejoin the Foundation as a consultant with a pathway toward a full and proper re-integration. Such an arrangement was to be made cautiously, with an eye toward our shared mission, and free from public spectacle.

We regret to report that, effective immediately, Dr. de Grey will no longer be consulting with SRF.

It’s important to note that, as with our previous separation, this is not related to the findings of last year’s independent investigation. While those investigations did substantiate instances of poor judgment and boundary-crossing behaviors, Dr. de Grey is not a sexual predator. Rather, the termination of Dr. de Grey’s consultancy with the Foundation is entirely due to his unwillingness to comply with even the most basic conditions of the agreements he signed with advice from his counsel. In the spirit of transparency, you can access the signed contract here: LINK

The SRF staff is talented, positive, and dedicated to our cause. We want to ensure they can advance their work free from distraction. As a Board, this will become both our sole focus and our promise. Every one of our Directors has worked exhaustively to preserve this Foundation during an unprecedented, challenging time in our history. A number of our members need to move on to other endeavors, but we will be looking to expand the Board and further the cause in the near future. We are grateful for every member’s service and commitment to the longevity field, as well as their strength in making these difficult but necessary decisions.

It is SRF’s intention that we and Dr. de Grey can continue to work in a way that is aligned toward a common purpose: to cure the disease of aging. Until such time, we will do all we can to assure you we are navigating this situation in a manner that honors our mission and fiduciary duties while respecting the legacy of our founding.

Sincerely,

The SENS Research Foundation Board of Directors

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2022 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can